June 23, 2017
The Centers for Disease Control (CDC) reports that about two-thirds of the adult population in the United States is classified as either overweight or obese (BMI of >25 or >30). Obesity has been reported to increase the likelihood of various diseases and health problems including heart disease, type 2 diabetes, and metabolic syndrome. These diseases are commonly associated with insulin deficiencies, high serum triglyceride levels, hypertension and athergenic dyslipidemia, especially lower than normal levels of high-density lipoprotein (HDL) cholesterol. Previous studies have shown that D-tagatose, an isomer of fructose currently used as a low-calorie sweetener, is useful in reducing glycosylated hemoglobin in type 2 diabetes. Additionally, resveratrol has been reported to suppress the serum lipid peroxide levelsin vivo.However, both compounds have minimal effects on the prevention of treatment of metabolic syndrome, atherosclerosis, obesity and type 2 diabetes.
Researchers at the University of Kentucky have developed pharmaceutical compounds and methods for the prevention or treatment of atherosclerosis, the metabolic syndrome, obesity and diabetes. The invention includes a pharmaceutically effective amount of D-tagatose in combination with a pharmaceutically acceptable amount of a stilbene or stilbenoid component, or a salt or derivative thereof; or a combination thereof. The pharmaceutical compositions have shown to be more effective than D-tagatose or resveratrol alone in control of serum lipoproteins; lowering triglycerides and LDL while simultaneously raising HDL. Other advantages include a natural, FDA approved composition that is readily formulated into stable oral doses.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
reducing glycosylated hemoglobin
technology solution researchers
pharmaceutically acceptable amount
fda approved composition
stable oral doses
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium